Clinical Trials Logo

Clinical Trial Summary

An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03484520
Study type Interventional
Source AbbVie
Contact
Status Terminated
Phase Phase 1
Start date July 23, 2018
Completion date December 1, 2022